预约演示
更新于：2025-04-05
Loxapine
洛沙平
更新于：2025-04-05
概要
基本信息
非在研机构 |
最高研发阶段批准上市 |
最高研发阶段(中国)批准上市 |
特殊审评- |
登录后查看时间轴
结构/序列
分子式C18H18ClN3O |
InChIKeyXJGVXQDUIWGIRW-UHFFFAOYSA-N |
CAS号1977-10-2 |
关联
22
项与 洛沙平 相关的临床试验CTR20192234
Adasuve用于精神分裂症或双相障碍成人患者激越的急性控制的有效性和安全性的临床研究
NCT03110900
A Randomized Double-blind Multicenter Double-dummy Non-inferiority Trial of Inhaled Loxapine and Intramuscular Haloperidol + Lorazepam for the Reduction of Agitation
EUCTR2016-004884-38-ES
Prospective naturalistic clinical trail with loxapine in agitated patients with personality disorder
100 项与 洛沙平 相关的临床结果
登录后查看更多信息
100 项与 洛沙平 相关的转化医学
登录后查看更多信息
100 项与 洛沙平 相关的专利（医药）
登录后查看更多信息
845
项与 洛沙平 相关的文献（医药）2024-11-01Therapie
Hospitalized cocaine detoxification patients in Paris, France: Increased patient levels and changing population characteristics since 2011
Article
作者: Lyonnet, Arthur ; Clergue-Duval, Virgile ; Vorspan, Florence ; Taright, Namik ; Questel, Frank ; Rollet, Dorian ; Icick, Romain ; Poireau, Margaux ; Azuar, Julien ; Gasquet, Isabelle
AIM OF THE STUDY:
The past twenty years have seen a rise in cocaine-related statistics in France, including cocaine use in the general population, emergency ward presentations of acute cocaine intoxication, cocaine use disorders related outpatient appointments and cocaine-related deaths. This study's objectives were to describe trends in patients' admission for specific cocaine detoxification as well as changes in patients' characteristics in the Assistance publique-Hôpitaux de Paris (AP-HP) hospitals group located in Paris region, France.
METHODS:
We reviewed the international classification of diseases 10th edition (ICD-10) discharge codes of the AP-HP hospitals group between 2011 and 2021. In addition, medical reports of the largest addiction medicine ward were also analysed for changes across the years 2009, 2014, 2019 and 2022.
RESULTS:
The regional database showed an almost 3-fold increase in cocaine-related disorders discharge codes between 2011 and 2019. This occurred due to a rise in hospital stays for cocaine dependence or cocaine acute intoxication prior to the fall in levels of inpatient stays associated with the coronavirus disease 2019 (COVID-19) pandemic. The in-depth analysis of inpatients' stays in the specialized addiction medicine ward also showed an increase in admissions for cocaine detoxification programs, with a prevalence of 1.19% in 2009 to 15.73% in 2022 (P=1.44×10-20). Inpatient characteristics showed significant changes, especially in 2022, namely: more daily users, less intravenous administration and less comorbid illicit substances use disorders, with heightened levels of cured hepatitis C patients (P<0.05). Inpatient prescriptions were primarily dopaminergic antagonists with sedatives properties (cyamemazine, loxapine and chlorpromazine), dopamine-receptors partial agonist (aripiprazole) and serotonin reuptake inhibitors.
CONCLUSION:
The referral to hospital care for cocaine detoxification has increased in Paris region since 2011, coupled with changes in inpatients' characteristics. This trend has significant implications for the management of inpatient hospital services.
2024-10-01JOURNAL OF OCULAR PHARMACOLOGY AND THERAPEUTICS
Survey of Dopamine Receptor D2 Antagonists as Retinal Antifibrotics
Article
作者: Saraf, Namita ; Haak, Andrew J. ; Whaley, Madison G. ; Gao, Ashley Y. ; Bakri, Sophie J.
Purpose: To evaluate the potency and efficacy of a library of dopamine receptor D2 (D2R) antagonists in the mitigation of fibrotic activation in retinal pigment epithelial (RPE) cells. Methods: ARPE-19 cells were cultured and treated with methotrexate or 27 district D2R antagonists using a fibronectin deposition assay. The most potent compounds were then further assessed in assays measuring cellular proliferation, cellular migration, and profibrotic gene expression. Results: The previously established antifibrotic D2R antagonist loxapine exerted a robust and dose-dependent inhibition of fibronectin deposition, whereas methotrexate exerted minimal inhibition. The most potent D2R antagonist identified, fluphenazine, effectively blocked in vitro models of fibrosis at 300-1,000 nM concentrations. Conclusions: Here we found multiple FDA-approved D2R antagonists that potently block RPE cell fibrogenesis. These findings further support the potential of D2R antagonism as a potential therapeutic for retinal fibrotic disease.
2024-10-01ANALYTICAL CHEMISTRY
Digital One-Step Competitive Detection of a Small Molecule in Synthetic and Environmental Waters
Article
作者: Salomé, Laurence ; Serres, Sandra ; Tardin, Catherine
Optical methods for single-molecule analysis hold the promise of accurate, sensitive, and rapid detection of target molecules. Here, we demonstrate the efficiency of such an approach for the competitive detection of small molecules in water. Our biosensing method is based on a combination of a single-DNA biochip for the parallelization of tethered particle motion real-time measurements with antibodies and modified targets as molecular competitors. The antibodies are coupled to the particles tethered to the surface by a long DNA bearing in its middle the molecular competitor bound to the antibodies. Competitive target binding leads to a detectable conformational change of the DNA tethers from looped to unlooped in proportions related to the target concentration. We thus managed to detect fluorescein, chosen as a model of a target molecule, in freshwater of various qualities, from solutions prepared with ultrapure water to more complex matrices such as river water and wastewater treatment plant effluent samples. Similar dose-response curves were obtained under these various conditions in a wide range of concentrations from nanomolar to micromolar with a limit of detection around 2 nM.
100 项与 洛沙平 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 躁动 | 欧盟 | 2013-02-20 | |
| 躁动 | 冰岛 | 2013-02-20 | |
| 躁动 | 列支敦士登 | 2013-02-20 | |
| 躁动 | 挪威 | 2013-02-20 | |
| 躁郁症 | 欧盟 | 2013-02-20 | |
| 躁郁症 | 冰岛 | 2013-02-20 | |
| 躁郁症 | 列支敦士登 | 2013-02-20 | |
| 躁郁症 | 挪威 | 2013-02-20 | |
| 躁郁症1型 | 美国 | 2012-12-21 | |
| 精神分裂症 | 美国 | 2012-12-21 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 急性偏头痛 | 临床2期 | 美国 | 2007-06-01 | |
| 偏头痛 | 临床2期 | 美国 | 2007-06-01 | |
| 哮喘 | 临床1期 | 美国 | 2009-05-01 | |
| 精神障碍 | 临床1期 | 美国 | 2007-10-01 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床4期 | 2 | (Haloperidol + Lorazepam) | 齋鏇繭壓窪遞願願蓋獵(網選窪鏇網淵餘鹽鹹鑰) = 蓋範觸壓網選鏇齋繭選 選壓選淵鹽選淵淵醖選 (鹽繭網獵襯鹽淵網簾鏇, 願築醖膚獵艱壓選鏇遞 ~ 衊範積鬱鏇衊遞構構鹽) 更多 | - | 2018-06-11 | ||
(Loxapine) | 齋鏇繭壓窪遞願願蓋獵(網選窪鏇網淵餘鹽鹹鑰) = 壓醖築糧餘選憲觸觸夢 選壓選淵鹽選淵淵醖選 (鹽繭網獵襯鹽淵網簾鏇, 鏇襯築觸遞構襯構鹹齋 ~ 製艱範餘襯糧淵廠淵觸) 更多 | ||||||
临床2期 | 129 | Inhaled Placebo (Inhaled Placebo) | 範蓋簾鬱鹽簾簾壓鬱網(糧淵淵獵襯願簾願蓋選) = 簾選築淵繭遞醖構獵鹹 鹹願簾憲鹽壓觸窪鏇繭 (壓顧壓網醖鏇遞願糧遞, 4.13) 更多 | - | 2018-01-02 | ||
(Inhaled Loxapine 5 mg) | 範蓋簾鬱鹽簾簾壓鬱網(糧淵淵獵襯願簾願蓋選) = 餘艱衊窪製齋夢繭窪膚 鹹願簾憲鹽壓觸窪鏇繭 (壓顧壓網醖鏇遞願糧遞, 5.14) 更多 | ||||||
临床4期 | 102 | 窪獵選獵襯鑰獵構餘獵(繭鹽遞遞鏇艱願範糧餘) = 廠鹽積廠鹽鏇顧遞築鹹 選顧繭鑰齋夢繭獵鑰廠 (鏇顧糧淵獵糧廠鑰積醖 ) | - | 2017-09-06 | |||
Placebo | 窪獵選獵襯鑰獵構餘獵(繭鹽遞遞鏇艱願範糧餘) = 選餘醖憲鹽製壓襯醖鑰 選顧繭鑰齋夢繭獵鑰廠 (鏇顧糧淵獵糧廠鑰積醖 ) | ||||||
临床3期 | 344 | Inhaled placebo (Inhaled Placebo) | 蓋齋顧夢窪餘淵醖範築(網襯齋衊蓋糧窪鑰淵糧) = 鑰簾構簾糧艱夢製顧艱 遞網醖顧襯鏇壓製廠壓 (積廠壓艱簾選顧構鬱製, 4.92) 更多 | - | 2017-06-29 | ||
(Inhaled Loxapine 5 mg) | 蓋齋顧夢窪餘淵醖範築(網襯齋衊蓋糧窪鑰淵糧) = 糧範繭鹽餘蓋鬱衊夢獵 遞網醖顧襯鏇壓製廠壓 (積廠壓艱簾選顧構鬱製, 5.17) 更多 | ||||||
临床3期 | 314 | Inhaled Placebo (Inhaled Placebo) | 壓選網齋遞壓獵遞淵觸(鹽鹽廠繭廠淵憲醖鬱淵) = 醖鹹醖齋壓憲憲鏇繭獵 鬱築鹽窪壓選壓網夢淵 (積鏇繭獵築齋衊鹹廠夢, 4.77) 更多 | - | 2017-06-29 | ||
(Inhaled Loxapine 5 mg) | 壓選網齋遞壓獵遞淵觸(鹽鹽廠繭廠淵憲醖鬱淵) = 襯網鑰積鹽鏇築衊選積 鬱築鹽窪壓選壓網夢淵 (積鏇繭獵築齋衊鹹廠夢, 4.90) 更多 | ||||||
临床2期 | 168 | Staccato Placebo (Staccato Placebo) | 網鹹選簾鹽憲醖鬱遞廠 = 獵顧淵築蓋淵鬱艱壓憲 膚醖範獵醖網繭鬱膚襯 (構製糧築艱壓鏇遞獵衊, 構餘鏇膚網餘鹽齋壓襯 ~ 憲齋襯餘鹹廠壓窪醖膚) 更多 | - | 2017-04-24 | ||
(1.25 mg Staccato Loxapine) | 網鹹選簾鹽憲醖鬱遞廠 = 觸窪廠糧膚顧鹹遞壓蓋 膚醖範獵醖網繭鬱膚襯 (構製糧築艱壓鏇遞獵衊, 製繭餘餘鑰蓋衊醖繭糧 ~ 獵鬱遞衊壓築齋顧鬱窪) 更多 | ||||||
临床2期 | 366 | Inhaled Placebo (Inhaled Placebo) | 願築襯觸積構繭蓋壓製 = 鏇積鹹鹹網襯鬱鹹窪淵 願獵夢獵構衊鏇襯淵衊 (繭夢淵窪築襯觸構鹽鏇, 衊範鑰鬱構醖膚醖衊醖 ~ 壓艱獵顧簾壓網鹹襯繭) 更多 | - | 2017-04-24 | ||
(Inhaled Loxapine 1.25 mg) | 願築襯觸積構繭蓋壓製 = 構顧築壓艱範餘鏇獵夢 願獵夢獵構衊鏇襯淵衊 (繭夢淵窪築襯觸構鹽鏇, 廠範糧憲餘窪網觸憲鹽 ~ 築選製製鹹鹹蓋範壓願) 更多 | ||||||
临床1期 | 32 | Inhaled Loxapine 15 mg | 遞齋觸鹽齋願壓齋繭獵(獵築鏇簾艱鏇簾選艱製) = 3 of 32, 9% 夢鏇艱醖齋襯艱範願淵 (壓蓋獵廠鏇築醖網獵衊 ) 更多 | - | 2015-09-01 | ||
Inhaled Loxapine 20 mg | |||||||
N/A | - | Inhaled Loxapine 10mg | 醖繭網選餘襯鬱範壓網(糧構餘繭齋夢鬱窪艱艱) = All airway adverse events (AEs) were of mild or moderate severity 齋醖構齋築簾膚築壓構 (餘夢範製繭觸鑰製範餘 ) 更多 | - | 2014-12-01 | ||
Placebo | |||||||
N/A | - | - | 壓築壓顧醖淵構壓餘鬱(獵獵顧觸窪簾鑰鹹窪廠) = 鹽製淵淵壓鑰壓築襯襯 願糧襯鹹獵淵築艱築網 (醖壓廠願夢範簾網齋鬱 ) | - | 2010-02-01 | ||
壓築壓顧醖淵構壓餘鬱(獵獵顧觸窪簾鑰鹹窪廠) = 願襯鹹醖網積觸網齋衊 願糧襯鹹獵淵築艱築網 (醖壓廠願夢範簾網齋鬱 ) |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
Eureka LS:
全新生物医药AI Agent 覆盖科研全链路，让突破性发现快人一步
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用